Bayesian Capital Management, LP
- SEC CIK
- 0001632551
- Latest filing
- Aug 14, 2026
GSK holding history
GSK plc in every 13F filed by Bayesian Capital Management, LP, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
GSK overviewAll 13F holders of GSKFull Q2 2026 holdings
- Shares (Q2 2026)
- 18,100
- Value
- $948.8K
- % of portfolio
- 0.6%
- Quarters held
- 8
- Since Q1 2021
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q2 2026 | 18,100 | $948.8K | 0.6% | +18,100 | New | Holders |
| Q4 2025 | 0 | $0 | 0.0% | −10,295−100.0% | Sold out | Holders |
| Q3 2025 | 10,295 | $444.3K | 0.1% | +10,295 | New | Holders |
| Q2 2025 | 0 | $0 | 0.0% | −15,837−100.0% | Sold out | Holders |
| Q1 2025 | 15,837 | $613.5K | 0.1% | +1,800+12.8% | Added | Holders |
| Q4 2024 | 14,037 | $474.7K | 0.1% | +14,037 | New | Holders |
| Q3 2023 | 0 | $0 | 0.0% | −10,500−100.0% | Sold out | Holders |
| Q2 2023 | 10,500 | $374.2K | <0.1% | +10,500 | New | Holders |
| Q1 2023 | 0 | $0 | 0.0% | −24,320−100.0% | Sold out | Holders |
| Q4 2022 | 24,320 | $854.6K | 0.1% | −27,000−52.6% | Reduced | Holders |
| Q3 2022 | 51,320 | $1.51M | 0.3% | +51,320 | New | Holders |
| Q2 2021 | 0 | $0 | 0.0% | −34,825−100.0% | Sold out | Holders |
| Q1 2021 | 34,825 | $1.24M | 0.3% | – | – | Holders |
Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.